
    
      Patients are assigned to receive either denosumab 60mg sc (once) or placebo or daily
      teriparatide sc for three months or placebo.

      MRI examinations at baseline and after three months will be performed. Serum bone turnover
      markers will be evaluated as well as QoL questionnaires.
    
  